33,003 Shares in Genmab A/S (NASDAQ:GMAB) Purchased by Dean Capital Investments Management LLC

Dean Capital Investments Management LLC purchased a new position in Genmab A/S (NASDAQ:GMAB) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 33,003 shares of the company’s stock, valued at approximately $669,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Parametric Portfolio Associates LLC bought a new position in Genmab A/S during the 2nd quarter valued at about $6,937,000. Private Capital Group LLC bought a new position in Genmab A/S during the 2nd quarter valued at about $41,000. Signaturefd LLC bought a new position in Genmab A/S during the 3rd quarter valued at about $48,000. Envestnet Asset Management Inc. bought a new position in Genmab A/S during the 3rd quarter valued at about $2,698,000. Finally, Brinker Capital Inc. bought a new position in Genmab A/S during the 3rd quarter valued at about $988,000. Institutional investors own 1.37% of the company’s stock.

Genmab A/S stock traded up $0.04 during midday trading on Tuesday, hitting $22.12. The stock had a trading volume of 1,265 shares, compared to its average volume of 199,919. The stock has a fifty day moving average of $20.70. Genmab A/S has a 52-week low of $13.64 and a 52-week high of $22.20. The company has a current ratio of 18.72, a quick ratio of 18.72 and a debt-to-equity ratio of 0.01.

Genmab A/S (NASDAQ:GMAB) last released its earnings results on Wednesday, August 14th. The company reported $0.20 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.07 by $0.13. The firm had revenue of $116.49 million during the quarter. On average, analysts predict that Genmab A/S will post 0.5 EPS for the current year.

Several equities analysts have issued reports on the stock. Guggenheim assumed coverage on shares of Genmab A/S in a research note on Monday, August 12th. They set a “buy” rating on the stock. Morgan Stanley began coverage on shares of Genmab A/S in a research note on Monday, August 12th. They issued an “overweight” rating on the stock. Bank of America upgraded shares of Genmab A/S from a “neutral” rating to a “buy” rating in a research note on Friday, September 13th. HC Wainwright increased their price objective on shares of Genmab A/S from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Wednesday, October 16th. Finally, JPMorgan Chase & Co. upgraded shares of Genmab A/S from a “neutral” rating to an “overweight” rating and set a $23.00 price objective on the stock in a research note on Thursday, September 12th. Six investment analysts have rated the stock with a buy rating, Genmab A/S has an average rating of “Buy” and an average price target of $23.67.

Genmab A/S Company Profile

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).

Read More: Why are analyst ratings important in trading stocks?

Want to see what other hedge funds are holding GMAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genmab A/S (NASDAQ:GMAB).

Institutional Ownership by Quarter for Genmab A/S (NASDAQ:GMAB)

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit